Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Supemtek

- PMLiVE

GSK, Pfizer and Sanofi among drugmakers planning price hikes in US

Pricing pressures increase amid intense political scrutiny

- PMLiVE

AbbVie’s JAK inhibitor Rinvoq approved in EU for rheumatoid arthritis

Continued expansion for next-generation immunology drug

Sanofi reception

Sanofi narrows focus, shedding diabetes and cardiovascular research

New CEO Paul Hudson reveals strategy update

- PMLiVE

Sanofi’s sutimlimab set for filing in rare autoimmune anaemia next year

Late-stage candidate hit the mark in phase 3 study

- PMLiVE

Sanofi’s new CEO cuts first deal, adding Synthorx for $2.5bn

Acquisition bolsters immuno-oncology pipeline

Sanofi reception

Sanofi said to be looking at options for $30bn consumer health unit

Rumoured plans come ahead of strategic update meeting next month

- PMLiVE

J&J’s new Darzalex formulation OK’d for use in Europe

Extends use of multiple myeloma therapy even further

- PMLiVE

Takeda’s dengue vaccine seems safe with no prior virus exposure

Appears unaffected by serious safety issue affecting Sanofi rival

- PMLiVE

Trial backs Inovio/Sanofi combo in hard-to-treat brain cancer

Results at six months demonstrated 75% of patients were progression-free

- PMLiVE

Sanofi reveals positive phase 3 results for long-acting insulin Toujeo

Hopes new product can offset continuing decline in franchise

- PMLiVE

Sanofi settles Lemtrada dispute with Genzyme investors for $315m

The MS drug has been in decline amid increased market competition

- PMLiVE

Dupixent gains can’t keep Sanofi on a growth track

Reports fall in Q3 sales despite growth of immunology drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links